NDLI: Safety profile of abatacept in rheumatoid arthritis: a review.

Please wait, while we are loading the content...

Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.

Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial.

Reversal of refractory sulfasalazine-related renal failure after treatment with corticosteroids.

Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia.

Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients.

Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks.

Assessing treatment effects in the 'real world'.

Does type of bolus insulin matter in the hospital? Retrospective cohort analysis of outcomes between patients receiving analogue versus human insulin.

Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteers.

Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study.

Year: 2010 Volume: 32 Issue: 10

Year: 2010 Volume: 32 Issue: 9

Year: 2010 Volume: 32 Issue: 8

Year: 2010 Volume: 32 Issue: 7

Year: 2010 Volume: 32 Issue: 6

Year: 2010 Volume: 32 Issue: 5

Year: 2010 Volume: 32 Issue: 4

Year: 2010 Volume: 32 Issue: 3

Year: 2010 Volume: 32 Issue: 2

Year: 2010 Volume: 32 Issue: Supplementary 2

Year: 2010 Volume: 32 Issue: 1

Year: 2010 Volume: 32 Issue: Supplementary 1

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

Safety profile of abatacept in rheumatoid arthritis: a review.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Khraishi, Majed Russell, Anthony Olszynski, Wojciech P.
Description	Country affiliation: Canada Author Affiliation: Khraishi M ( Memorial University of Newfoundland, St. John's, Newfoundland, Canada. mkhraishi@nexusresearch.com)
Abstract	BACKGROUND: Abatacept, a soluble human fusion protein that selectively modulates the costimulatory signal required for full T-cell activation, is approved for the treatment of rheumatoid arthritis (RA) in the United States, Canada, and the European Union. Because rare but serious adverse effects have been associated with biologic therapies, it is important to assess the safety profiles of these agents on an ongoing basis. OBJECTIVE: This article reviews current evidence on the safety profile of abatacept in patients with RA. METHODS: PubMed/MEDLINE was searched for clinical trials of abatacept using the terms abatacept OR CTLA4Ig, rheumatoid arthritis, and safety. Searches of abstracts presented at the 2007-2009 annual meetings of the American College of Rheumatology, European League Against Rheumatism, and Canadian Rheumatology Association were also conducted. Reports from clinical trials of at least 6 months' duration that evaluated abatacept in adults with RA were included in the review. RESULTS: Seven placebo-controlled trials and 1 open- label trial were included in the review, as were the long-term extensions of 5 of the studies and an integrated safety analysis. Abatacept added to methotrexate had an acceptable safety profile in patients with RA who had an inadequate response to methotrexate or other traditional disease-modifying antirheumatic drugs, or who failed to respond to treatment with anti-tumor necrosis factor agents. In the 5 core trials, discontinuations due to adverse events ranged from 1.9% to 8.7% of abatacept recipients and 0.9% to 4.3% of placebo recipients. In the integrated safety analysis, serious infections were reported in 3.0% of abatacept recipients and 1.9% of placebo recipients; the corresponding rates of malignancies were 3.7% and 2.9%. No additional safety concerns emerged during up to 7 years of exposure in the long-term extension studies. Antibodies to abatacept developed in ≤3% of patients, with no association found between immunogenicity and adverse events. CONCLUSION: Based on the evidence reviewed, abatacept had an acceptable safety profile and was well tolerated in patients with RA.
File Format	HTM / HTML
ISSN	01492918
Issue Number	11
Volume Number	32
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2010-10-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Antirheumatic Agents Adverse Effects Arthritis, Rheumatoid Drug Therapy Immunoconjugates Abatacept Adult Animals Administration & Dosage Therapeutic Use Physiopathology Drug Therapy, Combination Humans Methotrexate Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis.

Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.

Rituximab and abatacept for rheumatoid arthritis.

Abatacept for rheumatoid arthritis

Use of leflunomide plus TNF- inhibitors in rheumatoid arthritis.

Abatacept for rheumatoid arthritis

Long-term safety of abatacept in patients with rheumatoid arthritis.

Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.

Psoriasiform drug eruption due to abatacept.

Safety profile of abatacept in rheumatoid arthritis: a review.

Similar Documents

Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis.

Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.

Rituximab and abatacept for rheumatoid arthritis.

Abatacept for rheumatoid arthritis

Use of leflunomide plus TNF- inhibitors in rheumatoid arthritis.

Abatacept for rheumatoid arthritis

Long-term safety of abatacept in patients with rheumatoid arthritis.

Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.

Psoriasiform drug eruption due to abatacept.

Safety profile of abatacept in rheumatoid arthritis: a review.